Non-medical Switching From Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies

<b>Please note:</b>The video accompanying this manuscript represents the opinions of the authors.<br><br> <b>Funding</b>AbbVie funded this review, was involved in the collection, analysis, and interpretation of the data, and in the writing, review, and approval of the publication. Article processing charges were funded by AbbVie.<br> <b>Disclosures</b>Syed Numan is a full-time employee of AbbVie and may own AbbVie stock or stock options. Freddy Faccin is a full-time employee of AbbVie and may own AbbVie stock or stock options. <b><br></b><b>Compliance with Ethics Guidelines:</b>This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.<br> <b>Copyright</b>The Authors 2018. This video is distributed under the terms of the Creative Commons Attribtuion Noncommercial Licence which permits any noncommerical use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. <b><br></b><b>Article full text</b><br>The full text of this article can be found here<b>.</b> <br><b>Provide enhanced content for this article</b><br>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <b>[e-mail]</b>.<br>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.<br>Other enhanced features include, but are not limited to:<br>• Slide decks• Videos and animations• Audio abstracts • Audio slides<br>